Show simple item record

dc.contributor.authorDeeb, Omar
dc.date.accessioned2018-09-09T12:25:40Z
dc.date.available2018-09-09T12:25:40Z
dc.date.issued2012-05-16
dc.identifier.issn2578-9589
dc.identifier.urihttps://dspace.alquds.edu/handle/20.500.12213/874
dc.description.abstractOne of the most important challenges that face medicinal chemists today is the design of new drugs with improved properties and diminished side-effects for treating human disease such as AIDS and others. Medicinal chemists began the process by taking a lead structure and then finding analogs exhibiting the preferred biological activities. Next, they used their experience and chemical insight to eventually choose a nominee analog for further development. This process is difficult, expensive and took a long time. The conventional methods of drug discovery are now being supplemented by shortest approaches made possible by the accepting of the molecular processes involved in the original disease. In this view, the preliminary point in drug design is the molecular target which is receptor or enzyme in the body as an option of the existence of known lead structure.en_US
dc.language.isoen_USen_US
dc.titleRecent Applications of Quantitative Structure-Activity Relationships in Drug Designen_US
dc.typeBook Chapteren_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record